Word

PAD-LOCK

Status

Dead

Status Code

602

Status Date

Tuesday, January 9, 2024

Serial Number

97716190

Mark Type

4000

Filing Date

Tuesday, December 13, 2022

Abandoned Date

Tuesday, December 26, 2023

Trademark Owner History

Enlaza Therapeutics, Inc.

Classifications

5 Pharmaceutical products, preparations, and substances for the treatment of cancer; cancer therapeutics, namely, anti-cancer preparations; novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors; biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer; pharmaceutical products consisting of covalent protein biologics; pharmaceutical products, namely, covalent protein drugs; pharmaceuticals products consisting of synthetic biology enabled covalent protein biologics; pharmaceutical products consisting of covalent protein drugs; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals

1 Chemical products for use in industry and science; reagents for use in scientific apparatus for chemical or biological analysis; reagents for medical research; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; enzymes for scientific use; cell culture media for use in scientific research; active chemical ingredients for use in the manufacture of anti-cancer drugs; laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors; antibodies for research use

42 Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs; research and development for the purpose of selective covalent modification of proteins; research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors; conducting clinical trials for others in the field of cancer therapeutics; biotechnology testing services, namely, synthetic chemistry, recombinant protein production, bioconjugation, testing, and analysis; research and development services in the field of antibody-drug conjugates, T cells, natural killer (NK) cells, and macrophage engaging antibodies; research and development services for the purpose of antibody engineering, namely, custom design and engineering of antibodies

Trademark Events

Jan 9, 2024

Abandonment Notice E-Mailed - Failure To Respond

Jan 9, 2024

Abandonment Notice E-Mailed - Failure To Respond

Jan 9, 2024

Abandonment - Failure To Respond Or Late Response

Sep 23, 2023

Notification Of Non-Final Action E-Mailed

Sep 23, 2023

Non-Final Action E-Mailed

Sep 23, 2023

Non-Final Action Written

Sep 16, 2023

Assigned To Examiner

Jan 10, 2023

New Application Office Supplied Data Entered

Dec 16, 2022

New Application Entered